GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grifols SA (FRA:OZTA) » Definitions » Revenue

Grifols (FRA:OZTA) Revenue : €5,380 Mil (TTM As of Sep. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Grifols Revenue?

Grifols's revenue for the three months ended in Sep. 2024 was €1,793 Mil. Its revenue for the trailing twelve months (TTM) ended in Sep. 2024 was €5,380 Mil. Grifols's Revenue per Share for the three months ended in Sep. 2024 was €2.64. Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was €7.69.

During the past 12 months, the average Revenue per Share Growth Rate of Grifols was 3.70% per year. During the past 3 years, the average Revenue per Share Growth Rate was 7.60% per year. During the past 5 years, the average Revenue per Share Growth Rate was 7.20% per year. During the past 10 years, the average Revenue per Share Growth Rate was 7.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, Grifols's highest 3-Year average Revenue per Share Growth Rate was 51.60% per year. The lowest was -5.60% per year. And the median was 7.80% per year.


Grifols Revenue Historical Data

The historical data trend for Grifols's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grifols Revenue Chart

Grifols Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5,098.69 5,340.04 4,933.12 6,063.97 6,591.98

Grifols Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23 Jun24 Sep24
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,663.46 1,597.48 1,769.55 1,817.91 1,792.96

Competitive Comparison of Grifols's Revenue

For the Drug Manufacturers - General subindustry, Grifols's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Grifols's Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Grifols's Revenue distribution charts can be found below:

* The bar in red indicates where Grifols's Revenue falls into.



Grifols Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €5,380 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Grifols  (FRA:OZTA) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Grifols Revenue Related Terms

Thank you for viewing the detailed overview of Grifols's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Grifols Business Description

Address
Avinguda de la Generalitat, 152, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.

Grifols Headlines

No Headlines